Cubist Systematic Strategies LLC bought a new stake in DBV Technologies SA – (NASDAQ:DBVT) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,114 shares of the company’s stock, valued at approximately $132,000.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in DBV Technologies in the 3rd quarter valued at approximately $146,000. Dynamic Technology Lab Private Ltd acquired a new stake in DBV Technologies in the 2nd quarter valued at approximately $222,000. Commonwealth Equity Services Inc acquired a new stake in DBV Technologies in the 3rd quarter valued at approximately $233,000. Highbridge Capital Management LLC acquired a new stake in DBV Technologies in the 3rd quarter valued at approximately $1,061,000. Finally, Sabby Management LLC acquired a new stake in DBV Technologies in the 2nd quarter valued at approximately $1,339,000. 46.92% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have issued reports on DBVT shares. Deutsche Bank raised their target price on DBV Technologies from $46.00 to $56.00 in a report on Sunday, October 8th. Zacks Investment Research raised DBV Technologies from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a report on Tuesday, October 24th. Morgan Stanley reaffirmed an “overweight” rating and issued a $72.00 target price (up previously from $70.00) on shares of DBV Technologies in a report on Friday, October 6th. JMP Securities began coverage on DBV Technologies in a report on Friday, November 17th. They set an “outperform” rating on the stock. Finally, Leerink Swann set a $49.00 price objective on DBV Technologies and gave the stock an “outperform” rating in a report on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. DBV Technologies currently has an average rating of “Buy” and a consensus target price of $49.63.
Shares of DBV Technologies SA – (NASDAQ DBVT) opened at $26.29 on Friday. DBV Technologies SA – has a fifty-two week low of $20.58 and a fifty-two week high of $50.57.
WARNING: This article was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thestockobserver.com/2018/01/14/3114-shares-in-dbv-technologies-sa-dbvt-purchased-by-cubist-systematic-strategies-llc.html.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Want to see what other hedge funds are holding DBVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DBV Technologies SA – (NASDAQ:DBVT).
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.